

**CENTER FOR DRUG EVALUATION AND RESEARCH**

***APPLICATION NUMBER:***

**50-720/S-001**

**ADMINISTRATIVE DOCUMENTS**  
**AND**  
**CORRESPONDENCE**

Date APR 3 1996

NDA No. 50-720

SMITHKLINE BEECHAM PHARMACEUTICALS  
1250 SOUTH COLLEGEVILLE ROAD  
P.O. BOX 5089  
COLLEGEVILLE, PA 19426-0989  
Attention: Peter J. Kitz  
Group Director  
U.S. Regulatory Affairs

Dear Sir/Madam:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: AUGMENTIN (Amoxicillin/Clavulanate Potassium) 875/125mg Tablets

NDA Number: 50-720

Supplement Number: S-001

Date of Supplement: MARCH 27, 1996

Date of Receipt: MARCH 28, 1996

Unless we find the application not acceptable for filing, the filing date will be 60 days from the receipt date above.

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research  
Attention: Document Control, Room 12B-30  
5600 Fishers Lane  
Rockville, MD 20857

Sincerely yours,

*IS/*  
Supervisory Consumer Safety Officer  
Division of Anti-Infective Drug Products  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Andy Yu  
10/17/02 05:02:50 PM  
CHEMIST

David Katague  
10/17/02 05:46:42 PM  
CHEMIST

**APPEARS THIS WAY  
ON ORIGINAL**